全胃切除术史患者超声内镜引导下肝空肠吻合术:多中心回顾性可行性研究(附视频)
该多中心回顾性研究纳入2011年5月至2023年2月法国3个和瑞士1个三级中心的全胃切除术史成人患者,评估超声内镜引导下肝空肠吻合术(EUS-HJS)的可行性与安全性。技术成功率100%(95%CI 85-100),临床成功率80%(95%CI 58-92),不良事件发生率33%(95%CI 17-55),胆管炎最常见;中位生存期6个月(IQR 1.5-12)。
要点
- EUS-HJS在全胃切除术史患者中技术成功率100%(95%CI 85-100),临床成功率80%(95%CI 58-92)。
- 不良事件发生率33%(95%CI 17-55),胆管炎最常见。
- 7例(39%)患者术后能接受抗癌治疗,中位生存期6个月(IQR 1.5-12)。
核心结论
- EUS-HJS对于因全胃切除术而解剖结构改变的患者是一种有效且可行的操作。
研究设计与样本
- 回顾性多中心研究,纳入2011年5月至2023年2月法国3个三级中心和瑞士1个三级中心所有接受EUS-HJS的成人患者,共21例有全胃切除术史的患者。
主要发现
- 技术成功率为100%(95%CI 85-100)。
- 临床成功率为80%(95%CI 58-92)。
- 记录的不良事件发生率为33%(95%CI 17-55),胆管炎是最常见的不良事件。
- 7例患者(39%)术后能够接受抗癌治疗。
- 中位生存期为6个月(四分位距1.5-12)。
关键数值与推荐
- 临床成功定义为瘙痒、黄疸和/或胆管炎消失;术后第一周内胆红素改善>30%和/或术后1个月内胆红素正常化也被视为临床成功的指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EUS-guided hepaticogastrostomy (EUS-HGS) is an effective biliary drainage technique for patients with altered anatomy or duodenal strictures. EUS-guided hepaticojejunostomy (EUS-HJS) can be used to create a fistula between the left hepatic duct and the jejunum in patients with a history of total gastrectomy. No specific data on this technique have been published. The aim of this study was to assess the feasibility and safety of EUS-HJS in patients with a history of total gastrectomy. METHODS: This retrospective multicenter study included all adult patients who underwent EUS-HJS at 3 tertiary French centers and 1 tertiary Swiss center between May 2011 and February 2023. The primary outcome was clinical success, which was defined as the disappearance of pruritus, jaundice, and/or cholangitis. An improvement in bilirubin >30% within the first week and/or bilirubin normalization within 1 month after the procedure were also considered indicators of clinical success. Secondary outcomes were technical success, rate of adverse events, need for endoscopic revision, possibility of resuming anticancer treatment, median survival, and technical differences compared with EUS-HGS. RESULTS: Twenty-one patients with history of complete gastrectomy who underwent EUS-HJS were included. Technical success was achieved in 100% of patients (95% confidence interval [CI], 85-100). Clinical success was achieved in 80% of patients (95% CI, 58-92). The incidence of recorded adverse events was 33% (95% CI, 17-55), with cholangitis being the most frequent adverse event. Seven patients (39%) were able to benefit from anticancer treatment after the procedure. Median survival time was 6 months (interquartile range, 1.5-12). CONCLUSIONS: EUS-HJS is an effective and feasible procedure for patients whose anatomy has been altered by total gastrectomy.
引用
- Balducci D, Ratone JP, Schaefer M, et al. EUS-guided hepaticojejunostomy in patients with history of total gastrectomy: a multicenter retrospective feasibility study (with video). Gastrointest Endosc. 2024. PMID: 39038522. doi:10.1016/j.gie.2024.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。